Protection from inflammatory bowel disease and colitis-associated carcinogenesis with 4-vinyl-2,6-dimethoxyphenol (canolol) involves suppression of oxidative stress and inflammatory cytokines

Carcinogenesis. 2013 Dec;34(12):2833-41. doi: 10.1093/carcin/bgt309. Epub 2013 Sep 24.

Abstract

Oxidative stress is associated with various pathological processes including inflammatory bowel disease, which is a major cause of colon cancer. Here, we examined the antioxidative and anti-inflammatory effects of 4-vinyl-2,6-dimethoxyphenol (canolol), a potent antioxidant compound obtained from crude canola oil. Oral administration of 2% dextran sulfate sodium (DSS) resulted in the progression of colitis with shortening of the large bowel length. Administering a diet containing canolol significantly suppressed pathogenesis; diarrhea markedly improved and the length of large bowel returned to almost normal. Pathological examination clearly revealed improvement of colonic ulcers. Production of inflammatory cytokines, i.e. interleukin-12 and tumor necrosis factor-α, was significantly increased during this pathological process; their production was markedly inhibited by canolol. In the azoxymethane/DSS-induced colon cancer model, mice receiving canolol had a reduced occurrence of cancer, to 60%, compared with control mice, 100% of which had colon cancer. The numbers of tumors in each mouse were also significantly reduced in mice receiving the canolol-containing diet (5.6±2.0) compared with azoxymethane/DSS control mice (10.8±4.2). No apparent toxicity of canolol was observed. Moreover, inflammatory cytokines (i.e. cyclooxygenase-2, inducible nitric oxide synthase and tumor necrosis factor-α) and oxidative responding molecules, i.e. heme oxygenase-1, in colon were suppressed during this treatment. In a mouse colon 26 solid tumor model, canolol significantly suppressed cyclooxygenase-2 expression; however, no significant tumor growth inhibition was observed, suggesting that canolol preferably shows chemopreventive effects during the stages of initiation/promotion. Canolol may, thus, be considered a potential cancer preventive agent or supplement.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / pharmacology
  • Antioxidants / pharmacology
  • Carcinogenesis / drug effects*
  • Carcinogenesis / metabolism
  • Colitis / chemically induced
  • Colitis / metabolism
  • Colitis / pathology*
  • Cyclooxygenase 2 / metabolism
  • Cytokines / metabolism*
  • Dextran Sulfate / adverse effects
  • Female
  • HEK293 Cells
  • Heme Oxygenase-1 / metabolism
  • Humans
  • Inflammatory Bowel Diseases / chemically induced
  • Inflammatory Bowel Diseases / metabolism
  • Inflammatory Bowel Diseases / pathology*
  • Macrophage Activation / drug effects
  • Mice
  • Mice, Inbred BALB C
  • Mice, Inbred ICR
  • Nitric Oxide Synthase Type II / metabolism
  • Oxidative Stress / drug effects*
  • Phenols / pharmacology*
  • Tumor Necrosis Factor-alpha / metabolism
  • Vinyl Compounds / pharmacology*

Substances

  • Anti-Inflammatory Agents
  • Antioxidants
  • Cytokines
  • Phenols
  • Tumor Necrosis Factor-alpha
  • Vinyl Compounds
  • Dextran Sulfate
  • Nitric Oxide Synthase Type II
  • Heme Oxygenase-1
  • Cyclooxygenase 2
  • PTGS2 protein, human
  • 4-vinyl-2,6-dimethoxyphenol